Alexion Pharmaceuticals (Alexion Pharmaceuticals) Total Inventories : $804 Mil (As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Total Inventories?

Alexion Pharmaceuticals's total inventories for the quarter that ended in Mar. 2021 was $804 Mil. Alexion Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2020 to the quarter that ended in Mar. 2021 was $790 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Alexion Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2021 was $-5.69.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Alexion Pharmaceuticals's Days Inventory for the three months ended in Mar. 2021 was 574.71.

Inventory Turnover measures how fast the company turns over its inventory within a year. Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Alexion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2021 was 0.48.

Alexion Pharmaceuticals Total Inventories Historical Data

The historical data trend for Alexion Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Total Inventories Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Inventories

Get a 7-Day Free Trial

374.70

460.40

472.50

627.60

775.70

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Total Inventories	Get a 7-Day Free Trial															586.80	577.70	729.00	775.70	803.90

Alexion Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Alexion Pharmaceuticals (NAS:ALXN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Alexion Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2021 is

	Net-Net Working Capital Per Share (Q: Mar. 2021 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3469.3	+	0.75 * 1473	+	0.5 * 803.9	-	6219.2
-	0	-	14.2)	/	220.9
=	-5.69

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Alexion Pharmaceuticals's Days Inventory for the three months ended in Mar. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2021 )	/	Cost of Goods Sold (Q: Mar. 2021 )	*	Days in Period
	=	789.8	/	125.4	*	365 / 4
	=	574.71

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2021 )	/	Average Total Inventories (Q: Mar. 2021 )
	=	125.4	/	789.8
	=	0.16

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alexion Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2021 )	/	Revenue (Q: Mar. 2021 )
	=	789.8	/	1636.5
	=	0.48

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Alexion Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974